Previous Close | 2.9000 |
Open | 2.9000 |
Bid | 2.2500 |
Ask | 2.6500 |
Strike | 17.50 |
Expire Date | 2024-12-20 |
Day's Range | 2.9000 - 2.9000 |
Contract Range | N/A |
Volume | |
Open Interest | 10 |
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
DUBLIN, May 28, 2024--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.
Celebrations may be in order for Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, with the analysts delivering a...